Abstract
In the United States, about 22,000 women will be diagnosed with ovarian cancer in 2011, and an estimated 14,000 patients will succumb to the disease [1]. Surgery and chemotherapy present the main treatment modalities, but despite the development of novel therapies, the overall 5 years survival for ovarian cancer patients with advanced disease at diagnosis remains at only about 30%. Novel therapeutic strategies are needed to prolong survival and achieve greater cure rates.
Matrix metalloproteinases (MMPs) are frequently expressed in ovarian cancer, and play an important role in the metastatic process. MMPs mediate degradation of the basement membrane as a crucial step in epithelial transformation, ovarian tumorigenesis and intraperitoneal metastasis [2]. Various preclinical and clinical studies have demonstrated that MMPs might provide a suitable therapeutic target. This review summarizes important observations regarding the expression of MMPs in ovarian cancer, their biological role, and data from clinical trials targeting MMPs in ovarian cancer patients.
Keywords: Batimastat, Clinical trial, Intraperitoneal, Ovarian cancer, Matrix metalloproteinase (MMP), Metastatic, Peptomimetic, Prinomastat, Serum marker, Tanomastat, Tissue Inhibitor of metalloproteinases (TIMP).
Anti-Cancer Agents in Medicinal Chemistry
Title:MMPs in Ovarian Cancer as Therapeutic Targets
Volume: 12 Issue: 7
Author(s): Amer Karam and Oliver Dorigo
Affiliation:
Keywords: Batimastat, Clinical trial, Intraperitoneal, Ovarian cancer, Matrix metalloproteinase (MMP), Metastatic, Peptomimetic, Prinomastat, Serum marker, Tanomastat, Tissue Inhibitor of metalloproteinases (TIMP).
Abstract: In the United States, about 22,000 women will be diagnosed with ovarian cancer in 2011, and an estimated 14,000 patients will succumb to the disease [1]. Surgery and chemotherapy present the main treatment modalities, but despite the development of novel therapies, the overall 5 years survival for ovarian cancer patients with advanced disease at diagnosis remains at only about 30%. Novel therapeutic strategies are needed to prolong survival and achieve greater cure rates.
Matrix metalloproteinases (MMPs) are frequently expressed in ovarian cancer, and play an important role in the metastatic process. MMPs mediate degradation of the basement membrane as a crucial step in epithelial transformation, ovarian tumorigenesis and intraperitoneal metastasis [2]. Various preclinical and clinical studies have demonstrated that MMPs might provide a suitable therapeutic target. This review summarizes important observations regarding the expression of MMPs in ovarian cancer, their biological role, and data from clinical trials targeting MMPs in ovarian cancer patients.
Export Options
About this article
Cite this article as:
Karam Amer and Dorigo Oliver, MMPs in Ovarian Cancer as Therapeutic Targets, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (7) . https://dx.doi.org/10.2174/187152012802650174
DOI https://dx.doi.org/10.2174/187152012802650174 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Druggable Orthosteric and Allosteric Hot Spots to Target Protein-protein Interactions
Current Pharmaceutical Design Bortezomib Enhances the Antitumor Effects of Interferon-β Gene Transfer on Melanoma Cells
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Oncological Submissions of Dendrimer
Current Pharmaceutical Design Ruxolitinib Regulates the Autophagy Machinery in Multiple Myeloma Cells
Anti-Cancer Agents in Medicinal Chemistry New Prospects for Nelfinavir in Non-HIV-Related Diseases
Current Molecular Pharmacology Armed Oncolytic Adenoviruses and Polymer-shielded Nanocomplex for Systemic Delivery
Current Cancer Therapy Reviews Preclinical Evaluation of New Taxoids
Current Pharmaceutical Design Recent Advances in Intervention in Markovian Regulatory Networks
Current Genomics Is Intake of Flavonoid-Based Food Supplements During Pregnancy Safe for the Developing Child? A Literature Review
Current Drug Targets Protein Phosphatase 1 and Its Complexes in Carcinogenesis
Current Cancer Drug Targets Highlights in Peptide Nanoparticle Carriers Intended to Oral Diseases
Current Topics in Medicinal Chemistry Targeting Thioredoxin Reductase: Anticancer Agents and Chemopreventive Compounds
Medicinal Chemistry The Impact of Gynecological Cancer on Reproductive Issues and Pregnancy:Psychological Implications
Current Women`s Health Reviews Adipose Derived Stem Cells for Musculoskeletal Regeneration: Recent Patents and Future Perspectives
Recent Patents on Regenerative Medicine Polymers Based on Phenyl Boric Acid in Tumor-Targeted Therapy
Anti-Cancer Agents in Medicinal Chemistry Neuropilin and Neuropilin Associated Molecules as New Molecular Targets in Pancreatic Adenocarcinoma
Anti-Cancer Agents in Medicinal Chemistry Targeting mTOR Signaling Pathway in Ovarian Cancer
Current Medicinal Chemistry Multifunctional Proteins in Tumorigenesis: Aminoacyl-tRNA Synthetases and Translational Components
Current Proteomics A Constrained Probabilistic Matrix Decomposition Method for Predicting miRNA-disease Associations
Current Bioinformatics Pharmacologic Evidence of Green Tea in Targeting Tyrosine Kinases
Current Reviews in Clinical and Experimental Pharmacology